JEFFREY MICHAEL DODD-O
Medical Practice in Baltimore, MD

License number
Pennsylvania MD037548E
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address 2
Baltimore, MD 21211
Pennsylvania

Personal information

See more information about JEFFREY MICHAEL DODD-O at radaris.com
Name
Address
Phone
Jeffrey M Dodd-O
13231 Greenbank Rd, Middle River, MD 21220
(410) 335-5728
Jeffrey M Dodd-O
1327 W 41St St, Baltimore, MD 21211
(410) 235-1526

Professional information

Jeffrey M Dodd-O Photo 1

Jeffrey M Dodd-O, Baltimore MD

Specialties:
Anesthesiologist
Address:
600 N Wolfe St, Baltimore, MD 21287
600 N Wolfe, Baltimore, MD 21287
Board certifications:
American Board of Anesthesiology Certification in Anesthesiology, American Board of Anesthesiology Sub-certificate in Critical Care Medicine (Anesthesiology)


Jeffrey Dodd-O Photo 2

Dr. Jeffrey Dodd-O, Baltimore MD - MD (Doctor of Medicine)

Specialties:
Critical Care Medicine
Address:
JOHNS HOPKINS HOSPITAL
600 N Wolfe St, Baltimore 21287
(410) 955-5080 (Phone), (410) 955-1464 (Fax)
Certifications:
Anesthesiology, 1994, Critical Care Medicine, 1997
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
JOHNS HOPKINS HOSPITAL
600 N Wolfe St, Baltimore 21287
The Johns Hopkins Hospital
1800 Orleans St, Baltimore 21287
Education:
Medical School
Medical College of Pennsylvania
Youngstown Hospital
Graduated: 1986
Johns Hopkins Hospital
Graduated: 1993
Graduated: 1994


Jeffrey Dodd-O Photo 3

Use Of An Nadph-Oxidase Inhibitor In The Treatment Of Reperfusion Injury

US Patent:
6090851, Jul 18, 2000
Filed:
Sep 9, 1998
Appl. No.:
9/150069
Inventors:
Jeffrey M. Dodd-o - Baltimore MD
David B. Pearse - Ellicott City MD
Assignee:
Johns Hopkins University School of Medicine - Baltimore MD
International Classification:
A61K 3119, A61K 3112, A61K 3111, A61K 31075, A61K 3105
US Classification:
514568
Abstract:
The present invention is directed to a method for the prophylactic and therapeutic treatment of reperfusion injury or injury due to a distal reperfusion. The method involves the administration of an NADPH-oxidase inhibitor to a cell, tissue, organ or animal in an amount sufficient to treat the cell, tissue, organ or animal for reperfusion injury prophylactically or therapeutically. The NADPH-oxidase inhibitor preferably is an o-methoxycatechol, or a pharmaceutically acceptable salt, derivative, dimer or prodrug thereof. Most preferably, the o-methoxycatechol is apocynin.